| CPC G16B 20/30 (2019.02) [A61K 39/0011 (2013.01); C12Q 1/708 (2013.01); G16B 35/00 (2019.02); G16C 20/60 (2019.02); G16H 10/40 (2018.01); G16H 20/10 (2018.01); G16H 20/40 (2018.01); G16H 70/60 (2018.01); A61K 39/00 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01)] | 17 Claims |
|
1. A method of treating a patient having a Human Papilloma Virus (HPV) viral infection, the method comprising:
obtaining a tissue sample from the patient and analyzing the tissue sample to obtain omics data;
comparing the omics data of the patient's tissue sample with omics data of a reference HPV viral genome to determine a plurality of nucleic acid sequences in the patient tissue sample encoding antigens for the HPV virus, wherein each of the antigens has a length of between 5 and 30 amino acids;
identifying an HLA-matched antigen from the plurality of nucleic acid sequences encoding antigens for the HPV virus, wherein the HLA-matched antigen is matched with respect to an HLA type of the patient and has a dissociation constant equal to or less than 100 nM with an HLA-type of the patient; and
treating the patient by administering to the patient having the HPV viral infection an effective amount of an immunotherapeutic composition comprising a recombinant virus that includes the nucleic acid encoding the HLA-matched antigen or a recombinant cell expressing a recombinant protein that targets the HLA-matched antigen, wherein the administration triggers an immune response against the HLA-matched antigen.
|